Clinical Trial Update: A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.

View source ↗

Summary

Post-marketing, observational study assessing safety of Refortrix (Tdap) administered during pregnancy in Brazil; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria

Drugs mentioned

• Refortrix (Tdap)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diphtheria | Status: COMPLETED | Results posted: 2019-10-01